Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 12/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | BRD4 | O60885 | 1/20 | 0.68 |
| ▸ | IKBKB | O14920 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | QPCT | Q16769 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514810 | 0.86 | TERT (0.70) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL6616416 | 0.86 | TERT (0.67) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL4649959 | 0.84 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL31322174 | 0.84 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL8515096 | 0.83 | TERT (0.67) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL6618127 | 0.82 | TERT (0.78) | TERTALDH1A1CYP3A4MAPTHPGD | |
| 7,8-Dihydroxyflavone SCHEMBL29374601 | 0.81 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| 7,8-Dihydroxyflavone SCHEMBL419316 | 0.81 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL35318 | 0.81 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL6614508 | 0.81 | TERT (0.73) | TERTALDH1A1CYP3A4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | claimed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4475837-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2023154896-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20220031641-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION | PHARMATROPHIX, INC. | 2022-02-03 | — | — | US | claimed |
| US-20210244768-A1 | CELL COMPOSITIONS AND USES THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2021-08-12 | — | — | US | claimed |
| EP-3813856-A1 | CELL COMPOSITIONS AND USES THEREOF | The University of Sydney (AU) | 2021-05-05 | — | — | EP | claimed |
| CN-112368004-A | Cell compositions and uses thereof | 悉尼大学 | 2021-02-12 | — | — | CN | claimed |
| WO-2019232594-A1 | CELL COMPOSITIONS AND USES THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2019-12-12 | — | — | WO | claimed |
| US-20160257930-A1 | NEURONAL STEM CELL DIFFERENTIATION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-09-08 | — | — | US | claimed |
| WO-2016112012-A1 | TRKB AGONISTS AS NOVEL TREATMENT FOR ACUTE AND CHRONIC CARDIAC DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-14 | — | — | WO | claimed |
| US-20160193296-A1 | METHODS FOR TREATMENT OF MICROCEPHALY ASSOCIATED AUTISM DISORDERS | BROWN UNIVERSITY OFFICE OF INDUSTRY ENGAGEMENT & COMMERCIAL VENTURING | 2016-07-07 | — | — | US | claimed |
| WO-2014100433-A1 | METHODS FOR TREATMENT OF MICROCEPHALY ASSOCIATED AUTISM DISORDERS | BROWN UNIVERSITY (US) | 2014-06-26 | — | — | WO | claimed |
| US-20140057837-A1 | METHODS AND COMPOSITIONS FOR THE \"BROWNING\" OF WHITE FAT | DURING MATTHEW (US) | 2014-02-27 | — | — | US | claimed |
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20110144196-A1 | TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF | EMORY UNIVERSITY (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2323649-A2 | TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF | Emory University (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010011836-A2 | TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF | EMORY UNIVERSITY (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031641-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION | CHRM3, CHAT, CHRM5 | TERT 2814/4885ALDH1A1 2748/4885CYP3A4 2633/4885 |
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | NTRK2, NTRK1, BDNF | TERT 2994/4885ALDH1A1 1653/4885CYP3A4 4808/4885 |
| US-20110144196-A1 | TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF | NTRK2, BDNF, HTR7 | TERT 3053/4885ALDH1A1 383/4885CYP3A4 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.